Polyclonal Rabbit anti‑Human OXSR1 / OSR1 Antibody (250‑330 aa, Internal, WB) LS‑C385253
Polyclonal Rabbit anti‑Human OXSR1 / OSR1 Antibody (250‑330 aa, Internal, WB) LS‑C385253
Antibody:
OXSR1 / OSR1 Rabbit anti-Human Polyclonal (250-330 aa, Internal) Antibody
Format:
Unconjugated, Unmodified
Overview
Antibody:
OXSR1 / OSR1 Rabbit anti-Human Polyclonal (250-330 aa, Internal) Antibody
Format:
Unconjugated, Unmodified
Specifications
Description
OSR1 antibody LS-C385253 is an unconjugated rabbit polyclonal antibody to OSR1 (OXSR1) (250-330 aa, Internal) from human. It is reactive with human and mouse. Validated for ELISA and WB.
Target
Human OXSR1 / OSR1
Synonyms
OXSR1 | Oxidative-stress responsive 1 | KIAA1101
Reactivity
Human, Mouse
(tested or 100% immunogen sequence identity)
Conjugations
Unconjugated
Purification
Immunoaffinity purified
Immunogen
Synthesized peptide derived from human OXSR1
Epitope
250-330 aa, Internal
Specificity
OXSR1 Polyclonal Antibody detects endogenous levels of OXSR1 protein.
Applications
- Western blot (1:500 - 1:2000)
- ELISA (1:40000)
Presentation
PBS, 0.02% Sodium Azide, 50% Glycerol, 0.5% BSA
Storage
Store at -20°C. Avoid freeze-thaw cycles.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
Featured Products
Species:
Mouse, Human
Applications:
IHC, Western blot, ELISA
Species:
Human, Mouse, Rat, Bovine
Applications:
IHC, IHC - Paraffin, Western blot
Species:
Human, Mouse, Rat
Applications:
IHC, IHC - Paraffin, Immunofluorescence, Western blot, ELISA
Species:
Human, Monkey
Applications:
ICC, Immunofluorescence, Western blot, Flow Cytometry
Species:
Human
Applications:
IHC, IHC - Paraffin, Immunofluorescence, Western blot, ELISA
Species:
Human
Applications:
Flow Cytometry, Functional Assay
Request SDS/MSDS
To request an SDS/MSDS form for this product, please contact our Technical Support department at:
Technical.Support@LSBio.com
Requested From: United States
Date Requested: 4/26/2024